To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate challenges associated with treating patients with RRMM and the clinical utility of agents that could signiícantly impact patient outcomes. This will include an awareness of the unique mechanisms of CAR T-cell therapies and bsAbs, as well as the associated risks and appropriate strategies for management. In addition, clinicians must be aware of emerging therapies for patients with refractory disease. With these resources, clinicians will be better prepared to improve care quality by selecting eìective and safe treatment for their patients, providing appropriate education for patients and caregivers, and supporting patients throughout their treatment journey.
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2025-01-03 06:00:00
- End Date: 2025-01-03 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 32500.0 - Is Kind Support: False Source: Legend - Amount: 10000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all